Zoledronate, Fractures, and Mortality after Hip Fracture  

Oleh:

Berg, Pieter van den (Editor)

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: The New England Journal of Medicine (keterangan: ada di Proquest) vol. 358 no. 09 (Feb. 2008), page 967.

Ketersediaan

Perpustakaan FK Nomor Panggil: N08.K.2008.01 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

To the Editor: The increased use of composite end points in clinical studies makes it harder for clinicians to translate the findings into treatment decisions. The Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly (HORIZON) Recurrent Fracture Trial, reported by Lyles et al. (Nov. 1 issue)1 is no exception. In this study, the primary end point was new clinical fractures, which included burdensome but relatively less severe fractures, such as vertebral fractures, and potentially life-threatening hip fractures. The absolute risk reduction for the primary end point was a significant 5.3%. However, the risk reduction for the clinically important .

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali